Disclosures for "Efficacy and Safety of Rimegepant for the Acute Treatment of Migraine in Black and African American Adults: Results From 3 Randomized, Placebo-Controlled Clinical Trials")
-
Dr. Charleston has received personal compensation in the range of $10,000-$49,999 for serving as a Consultant for Allergan/AbbVie. Dr. Charleston has received personal compensation in the range of $5,000-$9,999 for serving as a Consultant for Biohaven Biopharmaceuticals. Dr. Charleston has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Alder Biopharmaceuticals. Dr. Charleston has received personal compensation in the range of $5,000-$9,999 for serving as a Consultant for Teva Pharmaceuticals. Dr. Charleston has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Amneal Pharmaceuticals. Dr. Charleston has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Satsuma Pharmaceuticals. Dr. Charleston has received personal compensation in the range of $10,000-$49,999 for serving as an Expert Witness for Vaccine Injury Compensation Program. Dr. Charleston has a non-compensated relationship as a Associate Editor with Headache Journal: The Journal of Head and Face Pain that is relevant to AAN interests or activities. Dr. Charleston has a non-compensated relationship as a Board Member at Large with Alliance for Headache Disorders Advocacy that is relevant to AAN interests or activities.
-
Dr. Armand has received personal compensation in the range of $0-$499 for serving as a Consultant for Abbvie. Dr. Armand has received personal compensation in the range of $500-$4,999 for serving as a Consultant for TEVA. Dr. Armand has received personal compensation in the range of $5,000-$9,999 for serving as a Consultant for Spire Learning. Dr. Armand has received personal compensation in the range of $500-$4,999 for serving as an Editor, Associate Editor, or Editorial Advisory Board Member for JAMA Neurology.
-
Dr. Helveston has received personal compensation in the range of $500-$4,999 for serving on a Speakers Bureau for UCB. Dr. Helveston has received personal compensation in the range of $10,000-$49,999 for serving on a Speakers Bureau for Biogen. Dr. Helveston has received personal compensation in the range of $500-$4,999 for serving on a Speakers Bureau for Lundbeck. Dr. Helveston has received personal compensation in the range of $5,000-$9,999 for serving on a Speakers Bureau for BMS Pharmaceuticals. Dr. Helveston has received personal compensation in the range of $500-$4,999 for serving on a Speakers Bureau for Amgen. Dr. Helveston has received personal compensation in the range of $5,000-$9,999 for serving on a Speakers Bureau for Jazz Pharmaceuticals. Dr. Helveston has received personal compensation in the range of $10,000-$49,999 for serving on a Speakers Bureau for Abbvie. Dr. Helveston has stock in Biogen. An immediate family member of Dr. Helveston has received personal compensation in the range of $500-$4,999 for serving as a Spokesperson with Lundbeck.
-
Dr. Monteith has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Lundbeck . Dr. Monteith has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Impel . Dr. Monteith has received personal compensation in the range of $0-$499 for serving as a Consultant for Abbvie. Dr. Monteith has received personal compensation in the range of $500-$4,999 for serving as a Consultant for LinPharma. Dr. Monteith has received personal compensation in the range of $5,000-$9,999 for serving as a Consultant for Novartis. Dr. Monteith has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Lundbeck. Dr. Monteith has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Alder. Dr. Monteith has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Alder. Dr. Monteith has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Teva . Dr. Monteith has received personal compensation in the range of $500-$4,999 for serving as an Editor, Associate Editor, or Editorial Advisory Board Member for AAN . The institution of Dr. Monteith has received research support from AbbVie. The institution of Dr. Monteith has received research support from Amgen. The institution of Dr. Monteith has received research support from Teva. The institution of Dr. Monteith has received research support from Electrocore. The institution of Dr. Monteith has received research support from Novartis . The institution of Dr. Monteith has received research support from Amgen. The institution of Dr. Monteith has received research support from lilly. Dr. Monteith has received personal compensation in the range of $500-$4,999 for serving as a Education with Medscape. Dr. Monteith has received personal compensation in the range of $500-$4,999 for serving as a Education with Massachusetts Medical Society . Dr. Monteith has received personal compensation in the range of $500-$4,999 for serving as a Education with Academic CME. Dr. Monteith has received personal compensation in the range of $10,000-$49,999 for serving as a Education with Rockpointe. Dr. Monteith has received personal compensation in the range of $500-$4,999 for serving as a Speaker with Neuodiem. Dr. Monteith has a non-compensated relationship as a President Elect with Florida Society of Neurology that is relevant to AAN interests or activities. Dr. Monteith has a non-compensated relationship as a Editorial Board with American Migraine Foundation that is relevant to AAN interests or activities. Dr. Monteith has a non-compensated relationship as a Board Member with International Headache Society that is relevant to AAN interests or activities. Dr. Monteith has a non-compensated relationship as a author with Pfizer that is relevant to AAN interests or activities. Dr. Monteith has a non-compensated relationship as a author with Abbvie that is relevant to AAN interests or activities. Dr. Monteith has a non-compensated relationship as a author with Theranica that is relevant to AAN interests or activities.
-
The institution of Dr. O'Brien has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Medscape. The institution of Dr. O'Brien has received personal compensation in the range of $500-$4,999 for serving as a Consultant for GatherED . The institution of Dr. O'Brien has received personal compensation in the range of $0-$499 for serving as a Consultant for Guidepoint. The institution of Dr. O'Brien has received personal compensation in the range of $5,000-$9,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Lilly. The institution of Dr. O'Brien has received personal compensation in the range of $5,000-$9,999 for serving on a Scientific Advisory or Data Safety Monitoring board for BDSI. An immediate family member of Dr. O'Brien has received personal compensation in the range of $500-$4,999 for serving on a Speakers Bureau for Astra Zenica. The institution of Dr. O'Brien has received personal compensation in the range of $10,000-$49,999 for serving on a Speakers Bureau for Biohaven. The institution of Dr. O'Brien has received personal compensation in the range of $5,000-$9,999 for serving on a Speakers Bureau for Abbvie. The institution of Dr. O'Brien has received personal compensation in the range of $500-$4,999 for serving on a Speakers Bureau for BDSI. The institution of Dr. O'Brien has received personal compensation in the range of $500-$4,999 for serving on a Speakers Bureau for Amgen. The institution of Dr. O'Brien has received personal compensation in the range of $500-$4,999 for serving on a Speakers Bureau for PriMed. Dr. O'Brien has received personal compensation in the range of $0-$499 for serving as an officer or member of the Board of Directors for Ms. Medicine. Dr. O'Brien has received personal compensation in the range of $0-$499 for serving as an officer or member of the Board of Directors for 1N9. The institution of Dr. O'Brien has received research support from Abbvie. Dr. O'Brien has received publishing royalties from a publication relating to health care. Dr. O'Brien has a non-compensated relationship as a Accreditation Council Member with UCNS that is relevant to AAN interests or activities.
-
Dr. Croop has received personal compensation for serving as an employee of Biohaven Pharmaceuticals, Inc. Dr. Croop has stock in Biohaven Pharmaceutical Holding Co Ltd. Dr. Croop has received intellectual property interests from a discovery or technology relating to health care.
-
Alexandra Thiry has received personal compensation for serving as an employee of Biohaven Pharmaceuticals. Alexandra Thiry has received stock or an ownership interest from Biohaven Pharmaceuticals.
-
Beth Morris has received personal compensation for serving as an employee of Biohaven Pharmaceuticals Inc. Beth Morris has received stock or an ownership interest from Biohaven Pharmaceuticals Inc.
-
Micaela Forshaw has received personal compensation for serving as an employee of Biohaven Pharmaceuticals. Micaela Forshaw has received stock or an ownership interest from Biohaven Pharmaceuticals.
-
Dr. Abbott has received personal compensation for serving as an employee of Biohaven Pharmaceuticals, Inc. Dr. Abbott has stock in Biohaven Pharmaceuticals, Inc..